Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 3/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.38 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15181516 | 0.83 | MTOR (0.56) | NOTUMNPC1RAB9ASMN1; SMN2MTOR | |
| SCHEMBL18586054 | 0.83 | KMT2A (0.52) | NPC1RAB9ASMN1; SMN2MTORMGLL | |
| SCHEMBL18585571 | 0.83 | ALDH1A1 (0.49) | NPC1RAB9ASMN1; SMN2MTORMGLL | |
| SCHEMBL8415523 | 0.81 | MTOR (0.52) | NOTUMNPC1RAB9ASMN1; SMN2MTOR | |
| SCHEMBL18586055 | 0.81 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2MTORMGLL | |
| SCHEMBL70114 | 0.81 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2MTORRPTOR | |
| Water SCHEMBL17731583 | 0.80 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2MTORRPTOR | |
| SCHEMBL31398745 | 0.79 | GRM5 (0.54) | NOTUMNPC1RAB9ASMN1; SMN2MTOR | |
| SCHEMBL18586312 | 0.79 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2MTORRPTOR | |
| SCHEMBL11477159 | 0.79 | EPHX2 (0.63) | NOTUMNPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112368279-B | Novel compounds as mTOR inhibitors and uses thereof | 医药生命融合研究团 | 2024-05-28 | — | — | CN | disclosed |
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2023-05-16 | — | — | US | disclosed |
| US-20210292314-A1 | NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF | MEDICINAL BIOCONVERGENCE RESEARCH CENTER (KR) | 2021-09-23 | — | — | US | disclosed |
| EP-3786163-A1 | NOVEL COMPOUND AS MTOR INHIBITOR AND USE THEREOF | Medicinal Bioconvergence Research Center (KR) | 2021-03-03 | — | — | EP | disclosed |
| CN-112368279-A | Novel compounds as mTOR inhibitors and uses thereof | 医药生命融合研究团 | 2021-02-12 | — | — | CN | disclosed |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
| WO-2017040449-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
| CN-101018779-A | Triazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | CN | disclosed |
| US-20070185178-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | AATRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| EP-1720860-A1 | TRIAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-15 | — | — | EP | disclosed |
| US-20060019997-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-26 | — | — | US | disclosed |
| WO-2005080379-A1 | TRIAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023701-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | NOTUM 840/4885NPC1 3415/4885RAB9A 3993/4885 |
| US-11649231-B2 | Compound as mTOR inhibitor and use thereof | MTOR, RICTOR, RPTOR | NOTUM 1381/4885NPC1 162/4885RAB9A 500/4885 |
| US-20060019997-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | GRM3, GRIN3A, GRM1 | NOTUM 4056/4885NPC1 1874/4885RAB9A 2912/4885 |
| US-20070185178-A1 | Triazole compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRM3, GRIK5 | NOTUM 4132/4885NPC1 2690/4885RAB9A 1882/4885 |
| US-10407422-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | NOTUM 840/4885NPC1 3415/4885RAB9A 3993/4885 |
| US-20210292314-A1 | NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF | MTOR, RICTOR, RPTOR | NOTUM 1536/4885NPC1 172/4885RAB9A 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.